HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials - Prat, A; De Angelis, C; Pascual, T (J Clin Oncol, 2018)
(Suppl.)